Patent focus on cancer chemotherapeutics. II Angiogenesis agents: April 2000 - September 2000

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 1, 2001, Pages 77-114

  Connell, R D ^a   Beebe, J S ^a  

^a PFIZER INC   (United States)

Author keywords

v 3; 7E3; Angiogenesis; Angiopoietin; Angiostatin; Antibody; Arrestin; Canstatin; Cilengitide; Collagenase; Cytochalasin E; Endostatin; FGF; Flt; Fumagillin; HUVEC; Hydroxamate; Hypoxia; Integrin; KDR; Kininogen; Kringle; Marimastat; Matrix metalloproteinases (MMPs); Metallopharmaceuticals; Metastasis; MMp inhibitor (MMPI); Plasminogen; Platelet derived growth factor (PDGF); Prinomastat; PTK 787; Receptor tyrosine kinases inhibitors (TKIs); Restin; RGD; Stromelysin; SU 5416; SU 6668; Tek; Thrombospondin; Tie 2; TIMP; TKIs; TNP 470; Trk A; Tumour; Tumstatin; UPA; UPAR; Urokinase; Vascular endothelial growth factor (VEGF); Vasostatin; Vitronectin

Indexed keywords

2 AMINOBENZAMIDE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTHRANILIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BIPHENYL DERIVATIVE; COLLAGENASE 3; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; GELATINASE A; GELATINASE B; GUANIDINE DERIVATIVE; HYDROXAMIC ACID DERIVATIVE; INTEGRIN RECEPTOR; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; PLASMINOGEN ACTIVATOR INHIBITOR; PLATELET DERIVED GROWTH FACTOR; RECEPTOR BLOCKING AGENT; SB 267597; STROMELYSIN; SULFONAMIDE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VATALANIB;

ANGIOGENESIS; ANIMAL CELL; CANCER CHEMOTHERAPY; CHIRALITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; IC 50; MOUSE; NONHUMAN; PATENT; RECEPTOR BINDING; REVIEW; TUMOR VASCULARIZATION;

EID: 0035184875     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.1.77     Document Type: Review

References (62)

1. Vascular development: Cellular and molecular regulation
2. Regulators of colon cancer angiogenesis
3. Highest microvessel count as a long-term prognostic factor in Japanese breast cancer patients
4. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma
5. Angiogenesis inhibitors: Recent disappointments and long term prospects
6. Over 1,500 anticancer agents are in active development, with 522 in clinical trials, according to web-based new medicine's oncology knowledgeBASE
7. Ocular angiostatic agents
8. Cancer chemotherapeutics - Angiogenesis agents: October 1999-march 2000
9. 'Accidental' anti-angiogenic agents: Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples
10. Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases
11. Matrix metalloproteinases as emerging targets in anticancer therapy: Status and prospects
12. Matrix Metalloproteinases for treatment of cancer
13. Ongoing Trials with matrix metalloproteinase inhibitors
14. Metalloproteinase inhibitors: New opportunities for the treatment of rheumatoid arthritis and osteoarthritis
15. MMP inhibition as a potential therapeutic strategy for CHF
16. Design & synthesis of piperazine-based matrix metalloproteinase inhibitors
17. Privileged molecules for protein binding identified from NMR-based screening
18. Preclinical pharmacology of ABT-518, a novel and potent inhibitor of gelatinase A and B with anti-tumor activity
19. Novel N-hydroxamic acid hydrazide inhibitors of TNF-a synthesis
20. Angiopoietin/Tie receptor system: Emerging targets for therapeutic angiogenesis and anti-angiogenic therapy
21. The angiogenins: An emerging family of ribonuclease related proteins with diverse cellular functions
22. Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression and metastasis
23. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
24. Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors
25. Regulation of angiogenesis viavascular endothelial growth factor receptors
26. Vascular endothelial growth factor (VEGF) and its receptors
27. Vascular endothelial growth factor as a target for antiangiogenic therapy
28. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I
29. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II
30. Integrins as novel drug discovery targets: Potential therapeutic and diagnostic implications
31. Small molecule avintegrin antagonists: Novel anticancer agents
32. Several Angiogenesis inhibitors show potential in the lab
33. Cilengitide
34. Ligands to the integrin receptor avb3
35. Integrins as therapeutic targets
36. Identification and in vivo efficacy of small molecule antagonists of integrin avb3 (the vitronectin receptor)
37. Discovery of orally active non-peptide vitronectin receptor antagonists based on 2-benzazepine Gly-Asp-mimetic
38. Isoxazolines as potent antagonists of the integrin avb3
39. 3) receptor antagonists
40. 3 antagonists: Discovery of 5,6,7,8-tetrahydro[1,8]naphthyridine as a lipophilic, moderately basic guanidine replacement
41. Nonpeptide avb3 antagonists. 1. Transformation of a potent, integrin-selective aIIbb3 antagonist into a potent avb3 antagonist
42. Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor
43. Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation
44. Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model
45. Contortrostatin, a dimeric disintegrin from agkistrodon contortrix contortrix, inhibits angiogenesis
46. Disubstituted indazoles as potent antagonists of the integrin avb3
47. Radiopharmaceuticals for targeted radiotherapy in cancer
48. Antibodies to target integrins expressed on tumor vasculature
49. Plasminogen activator proteins tested as prognostic markers
50. Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin
51. Structure based design of novel urokinase inhibitors derived from 2-Naphthamidine
52. Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors
53. Angiogenesis team sued by pharmaceutical company
54. Folkman countersuit attacks 'fraudulent' Abbott
55. Antiangiogneic activity of the cleaved conformation of the serpin antithrombin
56. Cutting copper curbs angiogenesis, studies show
57. Anti-tumour activity of vascular targeting agent ZD6126 is enhanced by split dosing
58. Effects of angiogenesis inhibitor TNP-470 on tamoxifen-stimulated MCF-7 breast tumors in nude mice
59. TNP-470: An angiogenesis inhibitor in clinical development for cancer
60. Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbonyl) fumagillol (TNP-470) and its metabolites in AIDS patients with karposi's sarcoma
61. Kinase inhibitors in cancer therapy
62. Selective tyrosine kinase inhibitors